Jamie Kneebusch, PharmD, BCPS, BCPP

The panelists examined how early recognition of TD allows providers to optimize antipsychotic therapy and minimize or eliminate anticholinergic medications before patients progress to higher-burden treatment options such as clozapine.

Stephen Saklad, Melissa Cloyd, Jamie Kneebusch, and Farah Khorassani discussed the importance of ongoing provider re-education on TD, noting that many clinicians remain unfamiliar with the condition and its presentation, particularly given that effective vesicular monoamine transporter 2 (VMAT2) inhibitor treatments have only been available since 2017.